Search
Paclitaxel Treatment Options in California
A collection of 799 research studies where Paclitaxel is the interventional treatment. These studies are located in the California, United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
505 - 516 of 799
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Withdrawn
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2020
Locations: Local Institution, Bakersfield, California +4 locations
Conditions: Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Terminated
This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2020
Locations: Not set, West Hollywood, California
Conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
Completed
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of oral BAY1217389 given in combination with intravenous (IV) paclitaxel using an intermittent dosing schedule (2 days on / 5 days off) in subjects with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2020
Locations: Not set, Santa Monica, California
Conditions: Medical Oncology
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer.
PURPOSE: Randomized phase II/III trial to compare the effectiveness of paclitaxel and carboplatin with or without BMS-275291 in treating patients who have advanced or metastatic non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/02/2020
Locations: Scripps Clinic, La Jolla, California
Conditions: Lung Cancer
Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Completed
This randomized phase II trial studies how well giving cabozantinib-s-malate or paclitaxel works in treating patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cavity cancer. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/28/2020
Locations: Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California +5 locations
Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Completed
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with carboplatin and paclitaxel may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying how well erlotinib works when given alone or together with carbop... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/19/2020
Locations: Kaiser Permanente - Deer Valley, Antioch, California +35 locations
Conditions: Lung Cancer
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
Completed
This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Gender:
FEMALE
Ages:
All
Trial Updated:
02/18/2020
Locations: Long Beach Memorial Medical Center-Todd Cancer Institute, Long Beach, California +5 locations
Conditions: Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Steroid Cell Tumor
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
Completed
To obtain preliminary data in a randomized phase II study whether PPX/RT improves progression-free survival as compared to temozolomide/RT for patients with GBM without MGMT methylation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2020
Locations: UCSD Cancer Center, La Jolla, California
Conditions: Glioblastoma Multiforme
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Terminated
Determine whether viagenpumatucel-L combined with low-dose cyclophosphamide prolongs survival in patients with NSCLC who failed 2 or 3 prior lines of therapy for incurable or metastatic disease compared with chemotherapy alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2020
Locations: University of California San Diego, La Jolla, California +2 locations
Conditions: Non Small Cell Lung Cancer
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Completed
The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2020
Locations: Usc/Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Cancer
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Completed
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2020
Locations: City of Hope National Medical Center, Duarte, California +3 locations
Conditions: Advanced Cancer, Advanced Malignancies
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Completed
This randomized phase II trial studies how well nab-paclitaxel and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop the growth of tumor cells by binding to a protein called vascular endoth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2020
Locations: Saint Mary's Medical Center, San Francisco, California
Conditions: Metastatic Melanoma, Mucosal Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7, Unresectable Melanoma
505 - 516 of 799